SCHEMBL23212903

SCHEMBL23212903

Cc1c(Cl)cc(OC(N)=O)cc1CN1CCC(N(C)C)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.43
PARP2 Q9UGN5 1/20 0.43
KMT2A Q03164 4/20 0.36
L3MBTL3 Q96JM7 1/20 0.36
ATM Q13315 1/20 0.36
ALDH1A1 P00352 5/20 0.35
POLB P06746 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
RORC P51449 1/20 0.35
DDR1 Q08345 1/20 0.35
KDM4E B2RXH2 4/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TNKS O95271 1/20 0.34
MEN1 O00255 3/20 0.34
PLA2G1B P04054 1/20 0.34
ATG4B Q9Y4P1 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
LMNA P02545 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23213643 0.82 ALDH1A1 (0.42) KMT2AALDH1A1POLBTDP1KDM4E
SCHEMBL29177281 0.81 HCRTR1 (0.43) KMT2AALDH1A1POLBTDP1KDM4E
SCHEMBL29796167 0.78 PARP1 (0.40) PARP1PARP2ALDH1A1TDP1RORC
SCHEMBL23213143 0.78 PARP1 (0.40) PARP1PARP2ALDH1A1TDP1RORC
SCHEMBL27290092 0.78 RORC (0.40) PARP1PARP2KMT2AALDH1A1POLB
SCHEMBL23213615 0.77 CNR1 (0.41) PARP1PARP2KMT2AATMPOLB
SCHEMBL29716433 0.76 POLB (0.43) KMT2AALDH1A1POLBTDP1KDM4E
SCHEMBL23240247 0.76 POLB (0.43) KMT2AALDH1A1POLBTDP1KDM4E
SCHEMBL23213515 0.74 CHRNA3 (0.38)
SCHEMBL23213367 0.74 LMNA (0.51) PARP1PARP2KMT2AALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216355-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS MONTE ROSA THERAPEUTICS AG (CH) 2024-07-04 US disclosed
EP-4313047-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS Monte Rosa Therapeutics, Inc. (US) 2024-02-07 EP disclosed
WO-2021069705-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS (CH) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240216355-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS UPF1, NSUN2, RTF2 PARP1 4553/4885PARP2 3080/4885KMT2A 3292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.